Browsing by Author "Sandra Lane"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A Systematic Review of the Novel Targeted Immunobiological Medications in Rheumatoid Arthritis: Efficacy, Safety, and Innovation
    (Bentham Science Publishers, 2024-03-28) Sepideh Parchami Ghazaee; Kateryna Marchenko-Tolsta; Petro Sereda; Murtaza Hameed; Sandra Lane
    Introduction: Over the last half-century, the treatment and management of autoimmune rheumatic diseases have progressively improved, particularly with the contribution of immunobiological or biological therapies known as disease-modifying antirheumatic drugs. Although these agents have been generally efficient in the management of rheumatoid arthritis (RA), some patients experience limited efficacy and non-responsiveness to treatment. In addition, they may cause adverse clinical effects, further aggravating the disease. Objectives: Despite advancements in biological therapies, significant clinical needs persist. This review aims to discuss novel treatments, guiding future guidelines and drug discoveries for rheumatoid arthritis. Methods: This review follows the 2020 PRISMA statement, utilising PubMed and Google Scholar for literature search and emphasizing recent meta-analyses on the safety and efficacy of targeted immunobiological medications. Results: Small molecule inhibitors, whether utilised independently or in conjunction with Methotrexate, have been shown to contribute to effective disease management and have the potential for better adherence to the American College of Rheumatology criteria. Tocilizumab therapy demonstrates a significant reduction in disease activity and improves rates of disease remission when combined with Methotrexate. Investigations of mesenchymal stromal cell therapies have had promising outcomes, improving both cartilage quality (as evaluated by Macroscopic Cartilage Repair Assessment) and joint tenderness and swelling in clinical joint counts. Intra-articular administration of tolerogenic dendritic cells has displayed a capacity to alleviate pain, as measured by Visual Analog Scale scores, and enhance the Disease Activity Score across 28 joints. Resveratrol capsules supplemented with allopathic therapy show potential in reducing TNF-α and interleukin-6 serum levels. Conclusion: More investigations and their analysis will improve patient outcomes and reduce adverse effects and the costs involved in developing and obtaining immunobiological drugs. Moreover, assessing the safety and efficacy of anti-RA properties of the bioactive compounds could offer less toxic and more cost-effective natural treatment options.
  • No Thumbnail Available
    Item
    RENOPROTECTIVE PROPERTIES OF NOVEL ANTI-DIABETIC AGENTS
    (Primedia E-launch LLC, 2023-09-12) Sepideh Ghazaee; Kateryna Marchenko-Tolsta; Petro Sereda; Sandra Lane
    Chronic Kidney Disease (CKD) is the steady loss of renal function over time. CKD can also constitute abnormalities in the kidney structure. Kidney damage is measured using albuminuria, structural abnormalities, electrolytes and other abnormalities, prior kidney transplant or a projected glomerular filtration rate (eGFR) <60 mL/min/1.73 m [1]. Even though CKD has no known cure, its advancement can be slowed down by regulating the risk factors like high blood glucose levels, high blood pressure and dyslipidemia [2]. According to Mohamed et al. [3] diabetes accounts for almost 44% of all new CKD cases; this means that approximately 1 in 3 patients with diabetes also have kidney disease. For this reason, this investigation was chosen to analyze the agents that can regulate blood glucose levels while having renoprotective effects that have been shown to be enormously beneficial in this patient group.